EUVIMEDEUVIMED entdecken
Mixed-Methods-StudieOpen Access · CC BY-NC-ND 4.0

Burosumab Improves Patient-Reported Outcomes in Adults With Tumor-Induced Osteomalacia: Mixed-Methods Analysis

Suzanne M Jan de Beur iD, Tricia Cimms, Annabel Nixon iD, Christina Theodore-Oklota, Diana Luca, Mary Scott Roberts, Shayna Egan, Christina A Graham, Elizabeth Hribal, Christopher J Evans, Sue Wood, Angela Williams

Journal of Bone and Mineral Research · 2023

DOI: 10.1002/jbmr.4900 ↗

Kurz gefasst

Mixed-Methods-Studie in der Zeitschrift Journal of Bone and Mineral Research, 2023. Verfasst von Suzanne M Jan de Beur und 11 weiteren Autor:innen. Beteiligte Einrichtung: John Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Osteomalacia, Quality of Life. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kyowa Kirin International, Ultragenyx Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-induced osteomalacia (TIO) is an ultra-rare disease caused by tumors that secrete fibroblast growth factor 23, leading to chronic hypophosphatemia, poor skeletal health, and impaired physical function. In a phase 2 trial (UX023T-CL201; NCT02304367; n = 14), 48 weeks of burosumab treatment restored phosphate homeostasis, with improvements in skeletal health, functional mobility, and patient-reported pain, fatigue, and health-related quality of life (HRQL) (SF-36 v2). Here, we report an exploratory mixed-methods analysis of change from baseline after 144 weeks of burosumab treatment alongside qualitative data from exit interviews with 8 of 14 trial participants to evaluate meaningful treatment effects from a patient perspective. The interview subset (n = 8) reported pain and fatigue and compromised HRQL at baseline. In the interviews, participants reported that compromised HRQL and pain were the most important aspects of the disease to treat; both were considered more bothersome than fatigue and compromised physical function and activities of daily living. Improvements in pain and fatigue after treatment were reported, some of which achieved statistically and/or clinically meaningful thresholds. Furthermore, improvements in SF-36 v2 scores were most pronounced in the Physical Component Score and its Physical Function and Bodily Pain domains. Overall, the interview subset provided descriptions of symptomatic improvement and its clinical meaningfulness, including physical function, participation in activities of daily living, and mental well-being. Thus, this exploratory mixed-methods analysis provides deeper understanding of patients' perception of clinical meaningfulness beyond that articulated in validated patient-reported outcome instruments. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteomalaciaQuality of LifePainMineralsFibroblast Growth FactorsHumansActivities of Daily LivingAdultPatient Reported Outcome MeasuresFatigueAntibodies, Monoclonal, HumanizedParaneoplastic Syndromes

Stichwörter der Autor:innen

CELL/TISSUE SIGNALING > ENDOCRINE PATHWAYS > PTH/VITAMIN D/FGF23CLINICAL TRIALSDISORDERS OF CALCIUM/PHOSPHATETHERAPEUTICS > OTHER

Substanzen

MineralsFibroblast Growth FactorsburosumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • John Hopkins University School of Medicine, Baltimore, MD, USA.
  • Ultragenyx Pharmaceutical Inc, Novato, CA, USA.
  • Chilli Consultancy, Salisbury, UK.
  • Lumanity, Bethesda, MD, USA.
  • Kyowa Kirin International, Marlow, UK.

ORCID-Profile: Suzanne M Jan de Beur, Annabel Nixon

Förderung

  • Kyowa Kirin International
  • Ultragenyx Pharmaceutical

Zitieren

APA

Jan de Beur, S. M., Cimms, T., Nixon, A., Theodore-Oklota, C., Luca, D., Roberts, M. S., Egan, S., Graham, C. A., Hribal, E., Evans, C. J., Wood, S., & Williams, A. (2023). Burosumab Improves Patient-Reported Outcomes in Adults With Tumor-Induced Osteomalacia: Mixed-Methods Analysis. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.4900

Vancouver

Jan de Beur SM, Cimms T, Nixon A, Theodore-Oklota C, Luca D, Roberts MS, et al. Burosumab Improves Patient-Reported Outcomes in Adults With Tumor-Induced Osteomalacia: Mixed-Methods Analysis. Journal of Bone and Mineral Research. 2023. doi:10.1002/jbmr.4900

BibTeX
@article{JandeBeur2023,
  author = {Jan de Beur, Suzanne M and Cimms, Tricia and Nixon, Annabel and Theodore-Oklota, Christina and Luca, Diana and Roberts, Mary Scott and Egan, Shayna and Graham, Christina A and Hribal, Elizabeth and Evans, Christopher J and Wood, Sue and Williams, Angela},
  title = {Burosumab Improves Patient-Reported Outcomes in Adults With Tumor-Induced Osteomalacia: Mixed-Methods Analysis},
  journal = {Journal of Bone and Mineral Research},
  year = {2023},
  doi = {10.1002/jbmr.4900}
}
Kostenlos starten →